AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

Background: The receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) is overexpressed and an important therapeutic target in Head and Neck cancer (HNC). Cetuximab is currently the only EGFR-targeting agent approved by the FDA for treatment of HNC; however, intrinsic and acquired re...

Full description

Bibliographic Details
Main Authors: Bruce, J.Y (Author), Hong, S. (Author), Iida, M. (Author), Kostecki, K.L (Author), Kranjac, C.A (Author), Liu, P. (Author), Longhurst, C. (Author), McDaniel, N.K (Author), Salgia, R. (Author), Welke, N.B (Author), Wheeler, D.L (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
AXL
Cell Line, Tumor
cetuximab
Cetuximab
drug resistance
Drug Resistance, Neoplasm
epidermal growth factor receptor
ErbB Receptors
genetics
Head and neck cancer
Head and Neck Neoplasms
head and neck tumor
HER3
human
Humans
metabolism
neuregulin1
oncoprotein
protein tyrosine kinase
Proto-Oncogene Proteins
Receptor Protein-Tyrosine Kinases
Resistance
tumor cell line
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items